Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07040566 · ClinicalTrials.gov registry record · Phase 2
A Trial of Varenicline for E-cigarette Cessation
A Phase 2 study of Nicotine Dependence and Vaping, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
- 2
- Study locations
NCT07040566 is a Phase 2 study of Nicotine Dependence and Vaping that is actively recruiting participants, run by Yale University. The registered enrollment target is 326 participants, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (79% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07040566, a Phase 2 study of Nicotine Dependence and Vaping, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline 1mg BID
Study Locations (2)
Connecticut
- Yale Cancer Center/Smilow Cancer Hospital at Yale-New Haven - New Haven
South Carolina
- Hollings Cancer Center at MUSC (HCC) - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07040566
The ClinicalTrials.gov registry entry for NCT07040566 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 182-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (79% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07040566 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, South Carolina.
Frequently Asked Questions
What is clinical trial NCT07040566 about?
NCT07040566 is a clinical study titled "A Trial of Varenicline for E-cigarette Cessation". This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
What is the current status of trial NCT07040566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2025-10-14. Estimated completion is 2030-10-30.
What conditions does trial NCT07040566 study?
This clinical trial studies the following conditions: Nicotine Dependence, Vaping, E-cigarette Use.
What interventions are being tested in trial NCT07040566?
The interventions under investigation include: Placebo (DRUG), Varenicline 1mg BID (DRUG).
Who is sponsoring clinical trial NCT07040566?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07040566 being conducted?
This trial has 2 study locations across Connecticut, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
-
Treatment of Smoking Among Individuals With PTSD
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.